Breast Cancer Trial, By Invitation NCT07132749 Sponsor: Yeon Hee Park Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, By Invitation

NCT07132749
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are older than 19 years of age.
  • People who have been diagnosed with breast cancer (confirmed through a tissue sample) that has spread to other parts of the body or has advanced locally in a way that cannot be treated with surgery, with or without measurable tumours.
  • People whose breast cancer was already at an advanced/spread stage when first diagnosed, or whose cancer has spread to distant parts of the body after surgery intended to cure it.
  • People whose breast cancer tests show a specific protein level — either "HER2-positive" (high levels of HER2) or "HER2-low" (lower but detectable levels of HER2) — as determined by standard laboratory testing guidelines.
  • People whose general health and ability to carry out daily activities falls within an acceptable range (rated 0–2 on a standard medical scale, meaning able to care for themselves even if not always able to do heavy physical activity) (confirm with trial site).
  • People who are about to start their first round of a treatment called T-DXd (trastuzumab deruxtecan).
  • People who are scheduled to receive a medication called netupitant/palonosetron (NEPA) to help prevent nausea and vomiting caused by their cancer treatment, in line with its approved use.
  • People who agree to use a highly effective method of contraception or who cannot become pregnant. Accepted methods include: complete abstinence from sex (as a consistent lifestyle choice, not periodic); surgical removal of the uterus and cervix, or having the fallopian tubes tied at least six weeks before starting the study treatment; a male partner who has had a vasectomy at least six months before the screening visit (and is the only partner); or a combination of an intrauterine device (IUD/IUS) together with a barrier method such as a condom or diaphragm used with spermicide.
  • People who have given written consent to take part in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who experienced nausea or vomiting in the seven days before their first planned dose of T-DXd.
  • People who have cancer that has spread to the membranes surrounding the brain and spinal cord, or to the brain itself.
  • People who have had an allergic reaction to any ingredient in T-DXd or NEPA, or to a class of anti-nausea drugs known as 5-HT3 receptor antagonists.
  • People who are pregnant, suspected to be pregnant, or who are currently breastfeeding.
  • People who have any other illness or condition that the trial doctor believes could put them at unacceptable risk if they were to receive T-DXd or NEPA.
  • People who need to take certain other medications that may interfere with the trial treatments — including steroids, anti-nausea drugs, benzodiazepines, antipsychotics, or specific named medicines such as pimozide, terfenadine, astemizole, cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, fluvoxamine, certain antidepressants (SSRIs/SNRIs), ritonavir, or nelfinavir (confirm the full list with the trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
Yeon Hee Park
Registry
ClinicalTrials.gov
Start date
12 August 2025
Est. completion
30 June 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Complete response (CR: no emesis and no rescue medication)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov